- Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
- The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
- Surmodics to Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call on October 31
- Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial
As of last trade
Surmodics Inc (SRDX:NSQ) traded at 39.30, 3.26% above its 52-week low of 38.06, set on May 20, 2019.
38.06May 20 201961.72Dec 07 2018
Markit short selling activity
|Market cap||533.28m USD|
|EPS (TTM)||0.5512 |
Data delayed at least 15 minutes, as of Nov 19 2019 20:28 GMT.